Disease · MONDO_0019087

cholangiocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cholangiocarcinoma. Diseases, record MONDO_0019087. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019087

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cholangiocarcinoma; Open Targets
Open Targets ID: MONDO_0019087; Open Targets
Other names: CC, CCA, Cholangiocar.- intra/extrahepatic, Cholangiocellular carcinoma, adult primary cholangiocarcinoma, adult primary cholangiocellular carcinoma, bile duct cancer, cholangiocarcinoma, intrahepatic and extrahepatic bile ducts (adenocarcinoma), cholangiocarcinoma, malignant, cholangiosarcoma, intrahepatic bile duct cancer (cholangiocarcinoma); Open Targets
Disease Ontology: DOID:4947; Disease Ontology
MeSH: D018281; MeSH
NCI Thesaurus: C4436; NCI Thesaurus
Orphanet: ORPHA:70567; Orphanet
Highest stage of its drugs: Approval, for 5 of its 144 drugs, from ClinicalTrials.gov, EMA Human Drugs, FDA and TTD; Open Targets

Drugs144

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMIGATINIB	CHEMBL4297522	Small molecule	Approval	EMA Human Drugs, FDA and TTD	11	8	8	Drugs and targets
IVOSIDENIB	CHEMBL3989958	Small molecule	Approval	EMA Human Drugs	8	6	6	Drugs and targets
FUTIBATINIB	CHEMBL3701238	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs and FDA	7	4	4	Drugs and targets
INFIGRATINIB	CHEMBL1852688	Small molecule	Approval	TTD	5	3	3	Drugs and targets
INFIGRATINIB PHOSPHATE	CHEMBL1834657	Small molecule	Approval	FDA	1	0	0	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	72	72	71	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	44	44	44	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	23	23	22	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	13	13	12	Drugs and targets

1 to 10 of 144

See all 144 drugs

Targets148

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FGFR1	Fibroblast growth factor receptor	10	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2260	Drugs and targets
PDCD1	Programmed cell death protein 1	10	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
FGFR2	Fibroblast growth factor receptor	9	Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2263	Drugs and targets
FGFR3	Fibroblast growth factor receptor	9	Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2261	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
EGFR	Epidermal growth factor receptor	7	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	7	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 148

See all 148 targets

Trials226

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02052778	A Study of TAS-120 in Patients With Advanced Solid Tumors	Phase 1/2	407	2024-03-20	Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer	FUTIBATINIB	Its record names the disease	ClinicalTrials.gov
NCT04083976	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations	Phase 2	316	2025-02-24	Advanced Solid Tumor	ERDAFITINIB	Its record names the disease	ClinicalTrials.gov
NCT03733990	A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)	Phase 1/2	216	2025-04-02	Cancer	BEXMARILIMAB	Its record names the disease	ClinicalTrials.gov
NCT01524978	A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers	Phase 2	208	2017-11-20	Multiple Myeloma, Neoplasms	CETUXIMAB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02989857	Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)	Phase 3	187	2022-04-13	Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma	IVOSIDENIB	Its record names the disease	ClinicalTrials.gov
NCT03474640	Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies	Phase 1	184	2024-11-22	Advanced Malignancies	TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT02924376	Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)	Phase 2	147	2023-02-23	Cholangiocarcinoma	PEMIGATINIB	Its record names the disease	ClinicalTrials.gov
NCT02150967	A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma	Phase 2	143	2022-07-15	Advanced Cholangiocarcinoma, FGFR2 Gene Mutation	INFIGRATINIB	Its record names the disease	ClinicalTrials.gov
NCT00789958	S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct	Phase 2	105	2016-09-22	Extrahepatic Bile Duct Cancer, Gallbladder Cancer	CAPECITABINE, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00661830	Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)	Phase 2	103	2013-11-21	Adenocarcinoma	GEMCITABINE, SORAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 226

See all 226 trials

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab vs Pooled Arm - Vemurafenib: serious adverse events	11 of 27	91 of 181	208	NCT01524978	Trial comparisons
Gemcitabine + Sorafenib vs Gemcitabine + Placebo: serious adverse events	33 of 49	35 of 48	97	NCT00661830	Trial comparisons
Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): deaths from any cause	35 of 43	35 of 43	86	NCT03201458	Trial comparisons
Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): serious adverse events	32 of 43	31 of 43	86	NCT03201458	Trial comparisons
Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: Number of Participants With Serious Adverse Events (SAEs)	10 of 29	0 of 17	46	NCT03773302	Trial comparisons
Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: Number of Participants With Adverse Events (AEs)	29 of 29	17 of 17	46	NCT03773302	Trial comparisons
Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: deaths from any cause	0 of 29	0 of 17	46	NCT03773302	Trial comparisons
Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: serious adverse events	10 of 29	0 of 17	46	NCT03773302	Trial comparisons
Stratum: 1 Prior Regimen vs Stratum 2: No Prior Therapy: serious adverse events	4 of 18	2 of 26	44	NCT00338988	Trial comparisons
Arm A - Cholangiocarcinoma vs ARM B - Pancreatic Cancer: Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)	5 of 13	19 of 30	43	NCT03250273	Trial comparisons

1 to 10 of 42

See all 42 comparisons in its trials

Papers from its trials128

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40713827	RESULT	1	PubMed
38319896	RESULT	1	PubMed
37368098	RESULT	1	PubMed
37075781	RESULT	1	PubMed
35022321	RESULT	1	PubMed
30998813	RESULT	1	PubMed
30914290	RESULT	1	PubMed
30178032	RESULT	1	PubMed
28420720	RESULT	2	PubMed
26324363	RESULT	1	PubMed

1 to 10 of 128

See all 128 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019087

GET https://conductscience.org/api/diseases/v1/MONDO_0019087/drugs?page=2

API reference For AI assistants